Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
6(46.2%)
Phase 2
4(30.8%)
N/A
2(15.4%)
Phase 3
1(7.7%)
13Total
Phase 1(6)
Phase 2(4)
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT01869595Completed

Thai MSM/TG Test and Treat Study

Role: collaborator

NCT05895955Phase 1Active Not Recruiting

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Role: collaborator

NCT01671982Phase 1Completed

ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment

Role: collaborator

NCT02383602Completed

Study to Evaluate the Feasibility of Community-based Test and Treat Strategies Among Men Who Have Sex With Men and Transgender Women to Increase the Uptake of HIV Testing and Treatment Services in Thailand

Role: collaborator

NCT04764422Phase 1Completed

Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand

Role: collaborator

NCT04548518Phase 3Unknown

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly

Role: collaborator

NCT05358873Not ApplicableCompleted

Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail

Role: collaborator

NCT00802334Phase 2Completed

TDM of Generic Lopinavir/Ritonavir 200/50 mg

Role: collaborator

NCT03390166Phase 2Completed

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Role: collaborator

NCT02894840Phase 1Completed

Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Role: collaborator

NCT01841918Phase 2Completed

Safety and Immunogenicity of Live Attenuated Influenza H5N2

Role: collaborator

NCT02229357Phase 2Completed

Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine

Role: collaborator

NCT00622141Phase 1Withdrawn

Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®

Role: collaborator

NCT00477126Phase 1Completed

Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®

Role: collaborator

NCT01364675Not ApplicableUnknown

Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects

Role: collaborator

All 15 trials loaded